Liver Cancer Clinical Trials

Ongoing Liver Cancer Trials @ NCIS - Patient Recruitment

Protocol Title and Number Principal Investigator

A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects with Hepatocellular Carcinoma Who Have Received Prior Sorafenib (EXELIXIS)

Dr Thomas Soh

An Open-Label, Multi-Center, Phase 1, Dose Escalation Study With Phase 2 Expansion Cohort to Determine the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma

Dr Thomas Soh


OPTIMIS: An international observational study to assess the use of sorafenib after transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC)


Dr Kieron Lim / Dr Yong Wei Peng

A Phase III, placebo-controlled, multi-center, randomized, doubleblind trial to evaluate the efficacy and safety of K-333 (peretinoin) in patients with complete cure of hepatocellular carcinoma in Asia K-333-3.01AS

A/Prof Lim Seng Gee

Phase III multi-centre open-label randomized controlled trial of selective internal radiation therapy (SIRT) versus Sorafenib in locally advanced hepatocellular Carcinoma (AHCC Protocol 06)

A/Prof Stephen Chang

A Phase III Clinical Trial of Intra-arterial Therasphere in the Treatment of Patients with Unresectable Hepatocellular Carcinoma (HCC): STOP-HCC (Biocompatibles Protocol Number TS-103)

A/Prof Stephen Chang

Updated as of 6 April 2015


Contact Information

Are you interested to participate in a clinical trial?

To find out if you are eligible for a particular clinical trial, please contact Ms Ong Geok Lan at